Every Form 4 that Immunic, Inc. (IMUX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IMUX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMUX filings page.
IMMUNIC, INC. director Elena Ridloff received a grant of 50,740 stock options on 2026-08-06. The options have an exercise price of $14.54 per share, are exercisable for 50,740 shares of common stock, vest in monthly installments over three years from the grant date, and expire on 2036-08-06. Following this grant, Ridloff holds 50,740 options directly.
IMMUNIC, INC. director Simona Skerjanec received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $14.80 per share and expire on July 5, 2036. They vest in monthly increments over one year from the grant date, and following this grant she holds 25,370 options directly.
IMMUNIC, INC. director Richard Alan Rudick received a grant of stock options covering 25,370 shares of common stock as equity compensation. The options have an exercise price of $14.80 per share, vest in monthly increments over one year from the grant date, and expire on July 5, 2036. Following this award, he directly holds 25,370 derivative securities.
IMMUNIC, INC. director Barclay A. Phillips received a grant of stock options that can convert into 25,370 shares of common stock. The options have an exercise price of $14.80 per share and expire on July 5, 2036. They vest in monthly increments over one year from the grant date, and after this award Phillips holds 25,370 stock options directly.
IMMUNIC, INC. director Joerg Neermann received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $14.80 per share and expire on July 5, 2036. They vest in monthly increments over one year from the grant date.
IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 25,370 shares of common stock at an exercise price of $14.80 per share. The option vests in monthly installments over one year from the grant date and expires on July 5, 2036. Following this grant, Congleton holds 25,370 options directly, with no accompanying share purchases or sales reported.
IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 50,740 shares of common stock. The options have an exercise price of $10.90 per share and were conditionally approved by the Board on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting on June 29, 2026. The options vest in 36 equal monthly installments from March 27, 2026, and expire on March 27, 2036, leaving Congleton with 50,740 options following this grant.
IMMUNIC, INC. director Simona Skerjanec received a grant of stock options covering 25,370 shares of common stock. The options carry an exercise price of $10.90 per share and are fully vested as of March 27, 2026. The grant was conditionally approved by the board on March 27, 2026 and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. Following this grant, Skerjanec holds 25,370 stock options directly.
IMMUNIC, INC. director Richard Alan Rudick received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share and expire on March 27, 2036.
The Board conditionally approved the grant on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which was obtained at the June 29, 2026 annual meeting. The option was fully vested as of March 27, 2026, and Rudick now holds options for 25,370 shares directly.
IMMUNIC, INC. director Tamar D. Howson received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share, are fully vested as of March 27, 2026, and expire on March 27, 2036. The grant was conditionally approved by the Board on March 27, 2026, subject to stockholder approval of an amendment to the company’s 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting of Stockholders held on June 29, 2026.
IMMUNIC, INC. director Joerg Neermann reported a grant of stock options on common stock. He received options on 25,370 shares at an exercise price of $10.90 per share, all of which are fully vested as of March 27, 2026.
The options were conditionally approved by the board on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan. That approval was obtained at the 2026 Annual Meeting of Stockholders on June 29, 2026. Following the grant, this option position totals 25,370 shares and there are no remaining derivative holdings shown beyond this grant.
IMMUNIC, INC. director Barclay A. Phillips received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share and are fully vested as of March 27, 2026. The grant was conditionally approved by the Board on March 27, 2026 and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. Following this award, Phillips holds options on 25,370 shares directly.
IMMUNIC, INC. reported that President and COO Jason Tardio received a grant of stock options covering 253,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on April 2, 2036. The grant was conditionally approved by the board and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting of Stockholders held on June 29, 2026. The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, aligning the executive’s compensation with longer-term company performance.
IMMUNIC, INC. Chief Financial Officer Glenn Whaley received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on April 2, 2036. The award was approved in connection with an amendment to the company’s 2019 Omnibus Equity Incentive Plan that stockholders approved at the 2026 Annual Meeting of Stockholders held on June 29, 2026. The underlying shares vest 25% on April 2, 2027, with the remaining portion vesting in equal monthly installments over the next 36 months. Following this grant, Whaley holds 120,000 options directly.
IMMUNIC, INC. director Daniel Vitt received a grant of stock options covering 445,000 shares of common stock as equity compensation. The options have an exercise price of $11.60 per share and expire on April 2, 2036, with all 445,000 options shown as held directly after the grant.
The grant was conditionally approved by the Board of Directors and became effective only after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the following thirty-six months, tying director compensation to longer-term company performance.
IMMUNIC, INC. director Michael W. Bonney received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $12.0800 per share and expire on May 15, 2036. They vest in thirty-six equal monthly installments starting on May 15, 2026, providing gradual future ownership potential if exercised. Following this grant, the filing shows Bonney holding options for 100,000 underlying shares.
IMMUNIC, INC. granted its Chief Executive Officer, Erik Lundgren, stock options covering 1,000,000 shares of common stock. The options have an exercise price of $13.05 per share and expire on May 22, 2036. They are time-vested: 25% vest on May 22, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on his continued employment.
Immunic, Inc. granted Chief Medical Officer Michael A. Panzara a stock option covering 300,000 shares of common stock. The option has an exercise price of $8.80 per share and expires on April 24, 2036, representing a compensation-related award rather than an open-market trade.
According to the vesting terms, 50% of the underlying 300,000 shares will vest on April 24, 2027, and the remaining 50% will vest in 24 equal monthly installments, as long as he remains an employee of Immunic in good standing through each vesting date.